Latest Curis News & Updates

See the latest news and media coverage for Curis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Curis

Clinical-stage cancer therapeutics company

curis.com

Headquarters: Lexington, United States
Founded year: 2000
Company type: Public company
Number of employees: 50–150
Industry: Biotechnology & Medical Research

Last updated November 3

Latest news about Curis

In short: Curis priced an $8.5 million private placement to fund operations through December 2026 CLL data

Company announcements

October 16 Curis

Curis prices $8.5 million at-the-market private placement

It sells 16,666,680 shares and warrants at $0.51 combined, amends prior warrants to $0.60, and expects proceeds to fund operations through December 2026 CLL data.

July 22 Curis

Curis reports positive updated emavusertib clinical data

PCNSL shows 86% ORR in BTKi-naïve and 26% in BTKi-experienced patients; year-end CLL data guidance rises to 5-10 patients.

July 1 Curis

Curis reports emavusertib clinical activity in lymphoma and AML

PCNSL ORR is 63% in BTK-naïve and 27% in BTKi-experienced patients; mFLT3 AML composite CR is 38% versus 21% for gilteritinib; cash is $15.0M.

December 31, 2016 Curis

Curis reports 2016 results and pipeline progress

It ended 2016 with $44.5 million in cash and raised $45 million in early 2017, while advancing CUDC-907 into Phase 2 and CA-170 into Phase 1.

Media coverage

November 3 Stock Titan

Curis proposes 1-for-5 to 1-for-12 reverse split

The board could implement an approved split within six months or abandon it. Fractional shares would round up, with no cash ...

July 21 Yahoo Finance

Curis Announces Positive Emavusertib Update

LEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...

February 2 The Globe and Mail

Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing

Curis ( (CRIS)) has issued an update. On February 3, 2026, Curis, Inc. became subject to a one-year Discretionary Panel Monitor under Nasdaq Listing Rule...

November 5, 2024 PR Newswire

Curis Provides First Quarter 2025 Business Update

LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...

Never miss news about Curis

Track Curis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Curis competitors & trending companies

Browse news for competitors to Curis and other trending companies.